Methylated E2F-1 Biomarker Detection for PRMT5 Inhibitor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective mechanisms to identify cancer susceptible to PRMT5 inhibition and determine if a subject will benefit from PRMT5 inhibitor treatment, as the mechanisms influencing E2F-1 activity and its apoptotic role in cancer cells remain elusive.
Innovation Solution
A method involving the use of an antibody specific to arginine-methylated E2F-1 protein to detect methylation levels, which indicates susceptibility to PRMT5 inhibition, and a kit for evaluating biological samples to determine the presence and concentration of methylated E2F-1 protein as a biomarker for responsive tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PRMT5 inhibition is used to treat cancer, then tumour cell death is achieved through E2F-1 activation, but the mechanism is not well understood and patient selection is difficult
Solution Approach 1:
The patent introduces methylated E2F-1 as an intermediary biomarker that mediates between PRMT5 inhibition and therapeutic effect. By detecting methylated E2F-1 levels in patient samples, clinicians can identify patients likely to respond to PRMT5 inhibition, thus resolving the uncertainty about treatment effectiveness without requiring complete mechanistic understanding.
Solution Approach 2:
The patent establishes a feedback loop where methylated E2F-1 serves as a measurable indicator of PRMT5 activity and treatment response. Monitoring methylated E2F-1 levels provides real-time feedback on treatment effectiveness, enabling dynamic adjustment of therapy and improving overall treatment reliability.
2Reliability
If PRMT5 inhibitor treatment is administered, then cancer treatment benefit is achieved, but patient selection and biomarker identification are lacking
Solution Approach 1:
The patent utilizes the detectability of methylated E2F-1 through specific staining techniques (analogous to color changes in detection) to visualize and quantify the biomarker in patient samples. This enables reliable differentiation between patients who will benefit from treatment and those who will not, solving the patient selection problem.
Solution Approach 2:
The patent replaces complex mechanistic analysis with a simpler biochemical detection system focused on methylated E2F-1. Instead of attempting to fully understand and measure all aspects of PRMT5 function and E2F-1 processing, the invention substitutes this complex system with a targeted detection approach that directly measures the functional output (methylated E2F-1) as a proxy for treatment response.
3Loss of information
If E2F-1 methylation is detected, then patient responsiveness is identified, but the complexity of the detection system increases
Solution Approach 1:
The patent extracts the critical information needed for patient selection by isolating and focusing on a single measurable feature - methylated E2F-1. By taking out only the essential biomarker signal from the complex cellular environment, the system achieves reliable patient responsiveness identification without requiring analysis of all cellular processes, thus reducing detection system complexity.
Solution Approach 2:
The patent segments the complex detection task into a focused measurement of methylated E2F-1 levels. Rather than attempting to measure all aspects of E2F-1 function, methylation status, and protein processing, the invention segments the approach to measure only the methylated form, which serves as a sufficient proxy for treatment responsiveness, thereby simplifying the detection system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the identification of cancer types that may benefit from PRMT5 inhibitor treatment by assessing methylation levels, potentially leading to targeted therapy and improved treatment outcomes.
Implementation Method 1
Arginine methylation is established as an important type of modification in protein control (Bedford and Richard 2005). A variety of processes are influenced by arginine methylation, including RNA splicing, chromatin and transcription control (Meister et al 2001; Pal et al 2004; Bedford and Richard 2005).
Implementation Method 2
According to a further aspect the invention provides an antibody which specifically binds to arginine-methylated E2F-1 protein, for example an antibody which specifically binds to a peptide comprising a sequence according to SEQ ID NO:5 or SEQ ID NO:6.
Data Source
Figure 1a
Figure 1b~1bii
Figure 1c~1d
AI summary
A method for the treatment of a proliferative disease comprising providing a E2F-1 protein which is arginine-methylation defective or administering a substance which reduces the expression and/or activity of PRMT5. The invention also provides antibodies, screening methods and kits.